Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Joris Hemelaar, University Research Lecturer and expert in maternal HIV infection at the Nuffield Department of Women's & Reproductive Health, published a new article: "Global and regional epidemiology of HIV-1 recombinants in 1990-2015" in the Lancet HIV.

Front cover of November 2020 Lancet HIV Journal

Global HIV-1 genetic diversity and evolution form a major challenge to treatment and prevention efforts. An increasing number of distinct HIV-1 recombinants have been identified worldwide (106 distinct recombinants to date), but their contribution to the global epidemic was hitherto unknown.

Dr Hemelaar's article: "Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey" is the first study to describe the global and regional distribution of HIV-1 recombinants (viruses that are the result of a cross-over between two or more different strains of HIV). This study is based on nearly 400,000 HIV samples covering the period 1990 to 2015. The global and regional distribution of HIV-1 recombinants was found to be extremely diverse and evolve over time. The number and proportion of recombinants is increasing worldwide, reaching 22.8% of global HIV-1 infections in 2010-2015. Recombinants play prominent roles in several regions, including in sub-Saharan Africa, East and South-east Asia, Middle East and North Africa, Eastern Europe and central Asia, and Latin America. This demonstrates the way the HIV pandemic is evolving and highlights the increasing challenge facing the development of a globally effective HIV vaccine as well as the need for ongoing adaptation of HIV diagnostic, drug resistance, and viral load assays.

The full story is available on the Nuffield Department of Women's and Reproductive Health website

Similar stories

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.

Oxford announces the founding of the new Bennett Institute for Applied Data Science

The Bennett Institute for Applied Data Science at the University of Oxford has been established to pioneer the better use of data, evidence and digital tools in healthcare and policy, optimizing the impact of interventions to achieve improved outcomes.